Anupam Rasayan India Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ompst9qw50whtqo5s1dvozrs.pdf

Key Takeaways


Revenue Recovery & Segment Performance

Thakkar: "No doubt always customer will want to have a cheaper product and quicker. But I think everybody has seen that now we have come to a level where we need to get to business on a steady-state basis."

Working Capital & Balance Sheet


New Contracts & Strategic Expansion

Desai: "This collaboration not only highlights Anupam's strength in fluorination and custom synthesis, but also reflects the trust global customers place in our quality manufacturing and technical capabilities."

LOI Execution & Growth Visibility

Thakkar: "If you look at my last 2 quarters' results, it gives me that much confidence and it provides a strong empirical evidence to that plan or the suggestion that I'm making."

Tariffs & External Risks

Thakkar: "If we look at the situation in terms of tariff from the U.S. one, I think today, a lot is fluid, I would say. And I would wait before make a conclusive statement."

Guidance & Commitments

CommitmentSpecificsTimeline
Working capital reductionSharp reduction in inventory and net working capital days; absolute reduction of a few hundred croresFY26, starting from Q2
Net working capital daysReach 180 daysOver the next 2 years
Revenue growthOver 30% YoYFY26
LOI revenueINR450-500 crores, doubling from last yearFY26
Performance materials mix15-20% of revenueFY26
Performance materials mix20-25% of revenueNext 2-3 years
Japan MPA commercializationSeveral molecules commercialized, production ramp-up followsCommercialization this year, ramp-up from next year
Debt-to-EBITDABelow 2x, pushing toward 1.5x or lessNot specified
Incremental margins25-27% on new businessNot specified
Tax rateHistorical averageOngoing

Key Metrics

MetricQ1 FY26
Consolidated revenue₹491 cr, +89% YoY
Consolidated revenue from operations₹486 cr, +91% YoY vs ₹254 cr in Q1 FY25
Consolidated EBITDA including other income₹129 cr, +118% YoY vs ₹59 cr in Q1 FY25; margin 26.3%
Consolidated profit after tax₹49 cr, +297% YoY vs ₹12 cr in Q1 FY25; margin 10%
Standalone revenue from operations₹316 cr, +93% YoY vs ₹164 cr in Q1 FY25
Standalone EBITDA including other income₹99 cr, +133% YoY vs ₹43 cr in Q1 FY25; margin 31%
Standalone profit after tax₹29.7 cr, vs ₹1.4 cr in Q1 FY25; margin 9.3%
Order book₹14,646 cr
Life sciences-related specialty chemicals revenue share88% of total revenue
Pharma segment revenue share24% of total revenue, vs 15% in Q1 FY25; 3x growth YoY
Performance materials revenue share12% of total revenue, vs 10% in Q1 FY25; over 2x growth YoY
Agrochem revenue share~57% of total revenue
Export share58% of revenue from operations
Top 10 customer concentration79% of revenue from operations
Gross debt~₹1,000 cr
Interest expense run rate₹26–27 cr per quarter
Debt-to-EBITDAless than 2x, targeting 1.5x or less
Working capital cycle target180 days over the next 2 years
FY26 revenue growth expectationover 30%
LOI contribution expected in FY26₹450–500 cr
Incremental margin guidance25–27%
Effective tax rate in Q1 FY2623%, lower due to credits